|
2018-12-26 |
2018-12-24 |
S
Sale
|
Gurney Austin
See Remarks
Officer
|
11,117
-14.3%
0.60
USD 6,669
|
11,117
-14.3%
|
0.60
|
USD 6,669
|
|
|
2018-10-11 |
2018-10-10 |
S
Sale
|
Li Yvonne
See Remarks
Officer
|
927
-1.5%
2.02
USD 1,873
|
927
-1.5%
|
2.02
|
USD 1,873
|
|
|
2018-10-11 |
2018-10-10 |
S
Sale
|
Stagg Robert
SVP, Clinical R&D
Officer
|
927
-2.2%
2.01
USD 1,863
|
927
-2.2%
|
2.01
|
USD 1,863
|
|
|
2018-10-11 |
2018-10-10 |
S
Sale
|
Lewicki John A.
President & CEO
Executive Director
|
1,156
-2.0%
2.01
USD 2,324
|
1,156
-2.0%
|
2.01
|
USD 2,324
|
|
|
2018-10-11 |
2018-10-10 |
S
Sale
|
Hager Alicia J.
SVP & General Counsel
Officer
|
1,156
-2.2%
2.02
USD 2,335
|
1,156
-2.2%
|
2.02
|
USD 2,335
|
|
|
2018-10-11 |
2018-10-10 |
S
Sale
|
Gurney Austin
See Remarks
Officer
|
1,156
-1.5%
2.01
USD 2,324
|
1,156
-1.5%
|
2.01
|
USD 2,324
|
|
|
2018-10-10 |
2018-10-09 |
S
Sale
|
Stagg Robert
SVP, Clinical R&D
Officer
|
1,686
-3.9%
2.13
USD 3,589
|
1,686
-3.9%
|
2.13
|
USD 3,589
|
|
|
2018-10-10 |
2018-10-09 |
PS
Planned sale
|
Li Yvonne
See Remarks
Officer
|
1,229
-2.0%
2.13
USD 2,616
|
1,229
-2.0%
|
2.13
|
USD 2,616
|
|
|
2018-10-10 |
2018-10-09 |
PS
Planned sale
|
Gurney Austin
See Remarks
Officer
|
1,686
-2.1%
2.13
USD 3,589
|
1,686
-2.1%
|
2.13
|
USD 3,589
|
|
|
2018-10-10 |
2018-10-09 |
PS
Planned sale
|
Lewicki John A.
President & CEO
Executive Director
|
2,296
-3.9%
2.13
USD 4,888
|
2,296
-3.9%
|
2.13
|
USD 4,888
|
|
|
2018-10-10 |
2018-10-09 |
S
Sale
|
Hager Alicia J.
SVP & General Counsel
Officer
|
1,686
-3.1%
2.13
USD 3,589
|
1,686
-3.1%
|
2.13
|
USD 3,589
|
|
|
2018-04-26 |
2018-04-24 |
S
Sale
|
Stagg Robert
SVP, Clinical R&D
|
4,051
-8.6%
2.68
USD 10,848
|
4,051
-8.6%
|
2.68
|
USD 10,848
|
|
|
2018-04-26 |
2018-04-24 |
S
Sale
|
Lewicki John A.
President & CEO
Executive Director
|
4,557
-7.6%
2.68
USD 12,202
|
4,557
-7.6%
|
2.68
|
USD 12,202
|
|
|
2018-04-26 |
2018-04-24 |
S
Sale
|
Gurney Austin
See Remarks
|
4,051
-5.0%
2.68
USD 10,848
|
4,051
-5.0%
|
2.68
|
USD 10,848
|
|
|
2018-04-26 |
2018-04-24 |
S
Sale
|
Li Yvonne
See Remarks
|
5,062
-7.8%
2.68
USD 13,555
|
5,062
-7.8%
|
2.68
|
USD 13,555
|
|
|
2018-04-26 |
2018-04-24 |
S
Sale
|
Hager Alicia J.
SVP & General Counsel
|
4,051
-6.9%
2.68
USD 10,848
|
4,051
-6.9%
|
2.68
|
USD 10,848
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
Hager Alicia J.
SVP & General Counsel
|
1,202
-2.0%
4.24
USD 5,099
|
1,202
-2.0%
|
4.24
|
USD 5,099
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
Hager Alicia J.
SVP & General Counsel
|
46
-0.1%
4.26
USD 196
|
46
-0.1%
|
4.26
|
USD 196
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
Patel Sunil
See Remarks
|
1,202
-1.7%
4.24
USD 5,099
|
1,202
-1.7%
|
4.24
|
USD 5,099
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
Patel Sunil
See Remarks
|
46
-0.1%
4.27
USD 196
|
46
-0.1%
|
4.27
|
USD 196
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
HASTINGS PAUL J
Chairman & CEO
|
1,346
-1.7%
4.24
USD 5,709
|
1,346
-1.7%
|
4.24
|
USD 5,709
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
HASTINGS PAUL J
Chairman & CEO
|
52
-0.1%
4.26
USD 222
|
52
-0.1%
|
4.26
|
USD 222
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
Gurney Austin
See Remarks
|
1,202
-1.5%
4.24
USD 5,099
|
1,202
-1.5%
|
4.24
|
USD 5,099
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
Gurney Austin
See Remarks
|
46
-0.1%
4.27
USD 196
|
46
-0.1%
|
4.27
|
USD 196
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
Lewicki John A.
EVP, Research & Development
|
1,202
-1.7%
4.24
USD 5,099
|
1,202
-1.7%
|
4.24
|
USD 5,099
|
|
|
2017-10-12 |
2017-10-10 |
S
Sale
|
Lewicki John A.
EVP, Research & Development
|
46
-0.1%
4.26
USD 196
|
46
-0.1%
|
4.26
|
USD 196
|
|
|
2017-06-07 |
2017-06-05 |
B
Purchase
|
KARSEN PERRY A
|
10,000
+inf%
3.46
USD 34,588
|
10,000
+inf%
|
3.46
|
USD 34,588
|
|
|
2017-05-26 |
2017-05-26 |
S
Sale
|
ROOT JONATHAN D
Non-Executive Director
|
3,222
-100.0%
3.70
USD 11,927
|
3,222
-100.0%
|
3.70
|
USD 11,927
|
|
|
2017-05-26 |
2017-05-26 |
S
Sale
|
ROOT JONATHAN D
Non-Executive Director
|
6,358
-100.0%
3.70
USD 23,536
|
6,358
-100.0%
|
3.70
|
USD 23,536
|
|
|
2017-05-26 |
2017-05-25 |
B
Purchase
|
LASERSOHN JACK W
Non-Executive Director
|
34,614
+22.9%
3.37
USD 116,639
|
34,614
+22.9%
|
3.37
|
USD 116,639
|
|
|
2017-05-26 |
2017-05-24 |
S
Sale
|
ROOT JONATHAN D
Non-Executive Director
|
1,447
-31.0%
3.72
USD 5,377
|
1,447
-31.0%
|
3.72
|
USD 5,377
|
|
|
2017-05-26 |
2017-05-24 |
S
Sale
|
ROOT JONATHAN D
Non-Executive Director
|
2,853
-31.0%
3.72
USD 10,601
|
2,853
-31.0%
|
3.72
|
USD 10,601
|
|
|
2017-05-25 |
2017-05-23 |
B
Purchase
|
LASERSOHN JACK W
Non-Executive Director
|
20,000
+15.3%
3.55
USD 71,000
|
20,000
+15.3%
|
3.55
|
USD 71,000
|
|
|
2017-05-22 |
2017-05-19 |
S
Sale
|
ROOT JONATHAN D
Non-Executive Director
|
2,519
-35.0%
3.70
USD 9,324
|
2,519
-35.0%
|
3.70
|
USD 9,324
|
|
|
2017-05-22 |
2017-05-19 |
S
Sale
|
ROOT JONATHAN D
Non-Executive Director
|
4,968
-35.0%
3.70
USD 18,388
|
4,968
-35.0%
|
3.70
|
USD 18,388
|
|
|
2017-05-18 |
2017-05-16 |
B
Purchase
|
LASERSOHN JACK W
Non-Executive Director
|
23,507
+21.8%
3.49
USD 82,061
|
23,507
+21.8%
|
3.49
|
USD 82,061
|
|
|
2017-05-18 |
2017-05-16 |
S
Sale
|
ROOT JONATHAN D
Non-Executive Director
|
2,321
-24.4%
3.58
USD 8,313
|
2,321
-24.4%
|
3.58
|
USD 8,313
|
|
|
2017-05-18 |
2017-05-16 |
S
Sale
|
ROOT JONATHAN D
Non-Executive Director
|
4,579
-24.4%
3.58
USD 16,401
|
4,579
-24.4%
|
3.58
|
USD 16,401
|
|
|
2017-04-05 |
2017-04-04 |
S
Sale
|
Patel Sunil
See Remarks
|
5,711
-18.9%
9.06
USD 51,731
|
5,711
-18.9%
|
9.06
|
USD 51,731
|
|
|
2017-04-05 |
2017-04-04 |
S
Sale
|
Patel Sunil
See Remarks
|
43
-0.1%
8.87
USD 382
|
43
-0.1%
|
8.87
|
USD 382
|
|
|
2017-04-05 |
2017-04-04 |
PS
Planned sale
|
Hoey Timothy
SVP, Cancer Biology & Co-CSO
|
5,711
-9.1%
9.06
USD 51,731
|
5,711
-9.1%
|
9.06
|
USD 51,731
|
|
|
2017-04-05 |
2017-04-04 |
PS
Planned sale
|
Hoey Timothy
SVP, Cancer Biology & Co-CSO
|
43
-0.1%
8.87
USD 381
|
43
-0.1%
|
8.87
|
USD 381
|
|
|
2017-04-05 |
2017-04-04 |
S
Sale
|
Hager Alicia J.
SVP & General Counsel
|
4,284
-16.6%
9.06
USD 38,805
|
4,284
-16.6%
|
9.06
|
USD 38,805
|
|
|
2017-04-05 |
2017-04-04 |
S
Sale
|
Hager Alicia J.
SVP & General Counsel
|
32
-0.1%
8.87
USD 284
|
32
-0.1%
|
8.87
|
USD 284
|
|
|
2017-04-05 |
2017-04-04 |
PS
Planned sale
|
HASTINGS PAUL J
Chairman & CEO
Executive Director
|
6,425
-16.5%
9.06
USD 58,199
|
6,425
-16.5%
|
9.06
|
USD 58,199
|
|
|
2017-04-05 |
2017-04-04 |
PS
Planned sale
|
HASTINGS PAUL J
Chairman & CEO
Executive Director
|
48
-0.1%
8.87
USD 426
|
48
-0.1%
|
8.87
|
USD 426
|
|
|
2017-04-05 |
2017-04-04 |
PS
Planned sale
|
Gurney Austin
See Remarks
|
5,711
-11.7%
9.06
USD 51,731
|
5,711
-11.7%
|
9.06
|
USD 51,731
|
|
|
2017-04-05 |
2017-04-04 |
PS
Planned sale
|
Gurney Austin
See Remarks
|
43
-0.1%
8.87
USD 381
|
43
-0.1%
|
8.87
|
USD 381
|
|
|
2017-04-05 |
2017-04-04 |
PS
Planned sale
|
Lewicki John A.
EVP, Research & Development
|
5,711
-19.9%
9.06
USD 51,731
|
5,711
-19.9%
|
9.06
|
USD 51,731
|
|
|
2017-04-05 |
2017-04-04 |
PS
Planned sale
|
Lewicki John A.
EVP, Research & Development
|
43
-0.1%
8.87
USD 381
|
43
-0.1%
|
8.87
|
USD 381
|
|
|
2017-03-17 |
2017-03-15 |
PS
Planned sale
|
Hager Alicia J.
SVP & General Counsel
|
6,652
-20.4%
10.00
USD 66,520
|
6,652
-20.4%
|
10.00
|
USD 66,520
|
|
|
2017-01-09 |
2017-01-06 |
PS
Planned sale
|
HASTINGS PAUL J
Chairman & CEO
Executive Director
|
21,369
-36.4%
8.52
USD 181,957
|
21,369
-36.4%
|
8.52
|
USD 181,957
|
|
|
2017-01-09 |
2017-01-05 |
PS
Planned sale
|
HASTINGS PAUL J
Chairman & CEO
Executive Director
|
21,369
-36.4%
8.17
USD 174,602
|
21,369
-36.4%
|
8.17
|
USD 174,602
|
|
|
2017-01-05 |
2017-01-03 |
PS
Planned sale
|
Hoey Timothy
SVP, Cancer Biology & Co-CSO
|
12,763
-17.3%
7.64
USD 97,448
|
12,763
-17.3%
|
7.64
|
USD 97,448
|
|
|
2017-01-05 |
2017-01-03 |
PS
Planned sale
|
Lewicki John A.
EVP, Research & Development
|
9,175
-22.5%
7.63
USD 70,045
|
9,175
-22.5%
|
7.63
|
USD 70,045
|
|
|
2016-11-18 |
2016-11-16 |
PS
Planned sale
|
Hoey Timothy
SVP, Cancer Biology & Co-CSO
Officer
|
12,500
-17.0%
9.89
USD 123,609
|
12,500
-17.0%
|
9.89
|
USD 123,609
|
|
|
2016-01-12 |
2016-01-11 |
PS
Planned sale
|
Dupont Jakob
SVP & Chief Medical Officer
Officer
|
2,500
-10.8%
20.01
USD 50,021
|
2,500
-10.8%
|
20.01
|
USD 50,021
|
|
|
2016-01-08 |
2016-01-07 |
S
Sale
|
Patel Sunil
See Remarks
Officer
|
1
-0.0%
21.33
USD 21
|
1
-0.0%
|
21.33
|
USD 21
|
|
|
2016-01-08 |
2016-01-07 |
S
Sale
|
Lewicki John A.
EVP & Chief Scientific Officer
Officer
|
1
-0.0%
21.33
USD 21
|
1
-0.0%
|
21.33
|
USD 21
|
|
|
2016-01-08 |
2016-01-07 |
S
Sale
|
Dupont Jakob
SVP & Chief Medical Officer
Officer
|
1
-0.0%
21.33
USD 21
|
1
-0.0%
|
21.33
|
USD 21
|
|
|
2016-01-08 |
2016-01-07 |
S
Sale
|
Hoey Timothy
SVP, Cancer Biology
Officer
|
1
-0.0%
21.33
USD 21
|
1
-0.0%
|
21.33
|
USD 21
|
|
|
2016-01-08 |
2016-01-07 |
S
Sale
|
Gurney Austin
See Remarks
Officer
|
1
-0.0%
21.33
USD 21
|
1
-0.0%
|
21.33
|
USD 21
|
|
|
2016-01-08 |
2016-01-07 |
S
Sale
|
Hager Alicia J.
VP & General Counsel
Officer
|
1
-0.0%
21.33
USD 21
|
1
-0.0%
|
21.33
|
USD 21
|
|
|
2016-01-08 |
2016-01-06 |
PS
Planned sale
|
HASTINGS PAUL J
Chairman & CEO
Executive Director
|
77
-0.3%
21.54
USD 1,659
|
77
-0.3%
|
21.54
|
USD 1,659
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Patel Sunil
See Remarks
Officer
|
69
-0.4%
21.65
USD 1,494
|
69
-0.4%
|
21.65
|
USD 1,494
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Lewicki John A.
EVP & Chief Scientific Officer
Officer
|
69
-0.4%
21.56
USD 1,488
|
69
-0.4%
|
21.56
|
USD 1,488
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Dupont Jakob
SVP & Chief Medical Officer
Officer
|
69
-0.3%
21.54
USD 1,486
|
69
-0.3%
|
21.54
|
USD 1,486
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Hoey Timothy
SVP, Cancer Biology
Officer
|
69
-0.1%
21.56
USD 1,488
|
69
-0.1%
|
21.56
|
USD 1,488
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Gurney Austin
See Remarks
Officer
|
69
-0.2%
21.54
USD 1,486
|
69
-0.2%
|
21.54
|
USD 1,486
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Hager Alicia J.
VP & General Counsel
Officer
|
52
-0.4%
21.54
USD 1,120
|
52
-0.4%
|
21.54
|
USD 1,120
|
|
|
2016-01-08 |
2016-01-06 |
PS
Planned sale
|
HASTINGS PAUL J
Chairman & CEO
Executive Director
|
2,335
-9.6%
22.30
USD 52,072
|
2,335
-9.6%
|
22.30
|
USD 52,072
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Patel Sunil
See Remarks
Officer
|
2,092
-10.5%
22.30
USD 46,653
|
2,092
-10.5%
|
22.30
|
USD 46,653
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Lewicki John A.
EVP & Chief Scientific Officer
Officer
|
2,092
-10.5%
22.30
USD 46,653
|
2,092
-10.5%
|
22.30
|
USD 46,653
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Dupont Jakob
SVP & Chief Medical Officer
Officer
|
2,092
-9.2%
22.30
USD 46,653
|
2,092
-9.2%
|
22.30
|
USD 46,653
|
|
|
2016-01-08 |
2016-01-06 |
S
Sale
|
Hoey Timothy
SVP, Cancer Biology
Officer
|
2,092
-4.2%
22.30
USD 46,653
|
2,092
-4.2%
|
22.30
|
USD 46,653
|
|
